Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
NCT ID: NCT04322734
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2023-12-13
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is currently recruiting.
There is no cost for visits or study-related exams.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Given the important role of the mitochondria in cellular function, individuals with classic mitochondrial disease demonstrate devastating symptoms, particularly in tissues that have high-energy demands such as the brain, muscles, gastrointestinal (GI) tract and immune system. Mitochondrial dysfunction contributes to the pathophysiology of more common diseases, including psychiatric diseases, neurodegenerative disorders, neurological disorders including migraine and seizures, persistent systemic inflammation, cardiac disease, cancer and diabetes. Mitochondrial dysfunction also effects a significant portion of individuals with autism spectrum disorder (ASD) as well as genetic syndromes associated with ASD.
One of our goals is to develop a method using the Seahorse Analyzer to measure individual variations in mitochondrial function which can identify children with medical disorders and mitochondrial dysfunction without an invasive muscle biopsy. In order to establish comprehensive profiles of mitochondrial function for individuals with known neurological and neurodevelopmental disorders, we will compare blood, urine, and stool from these individuals to those of healthy, typically developing (TD) children. The relationship between mitochondrial function, development, and behavior will be assessed by performing standard developmental testing. In addition, in patients who have a procedure that produces leftover tissue, we will examine the mitochondrial function in that tissue and correlate it with findings from blood.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASD (General)
150 children with ASD and unknown MD status
No interventions assigned to this group
ASD (With MD)
50 children with ASD and confirmed MD
No interventions assigned to this group
ASD (No MD)
50 children with ASD and ruled out MD
No interventions assigned to this group
Epilepsy
50 children with epilepsy (primary) and no ASD
No interventions assigned to this group
Brain Tumor
50 children with brain tumor (primary) and no ASD
No interventions assigned to this group
Psychiatric Disorder
50 children with psychiatric disorder (primary) and no ASD, using lithium treatments
No interventions assigned to this group
MD (No ASD)
50 children with MD (primary) and no ASD
No interventions assigned to this group
TD (With ASD Sibling)
50 TD children with a sibling with ASD/neurodevelopmental delay
No interventions assigned to this group
TD (No ASD Sibling)
50 TD children with no siblings with ASD/neurodevelopmental delay
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 0 years through 17 years 11 months of age
1\. 0 years to 17 years 11 months of age
Exclusion Criteria
2. In females of reproductive age, pregnancy or plans to become pregnant
3. Any other historical event/information that may, in the opinion of the PI, be a reason to exclude the child from participation.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
State University of New York - Downstate Medical Center
OTHER
Southwest Autism Research & Resource Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Richard Frye
Principal Investigator and Sponsor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richard E Frye, MD, PhD
Role: STUDY_DIRECTOR
Autism Discovery & Treatment Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southwestern Research and Resource Center
Phoenix, Arizona, United States
State University of New York, Downstate
Brooklyn, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christopher J Smith, PhD
Role: primary
Sophia Crisler
Role: backup
Harris Huberman, MD
Role: primary
Daniel Mishan
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Mito Tissue
Identifier Type: -
Identifier Source: org_study_id